A Simulation Model to Predict the Impact of Prophylactic Surgery and Screening on the Life Expectancy of BRCA1 and BRCA2 Mutation Carriers

Overview

Journal Cancer Epidemiol Biomarkers Prev

Specialties Biochemistry
Oncology
Public Health

Date 2012 May 5

PMID 22556274

Citations 18

Authors

Bronislava M Sigal

Diego F Munoz

Allison W Kurian

Sylvia K Plevritis

Affiliations

Soon will be listed here.

Abstract

Background: Women with inherited mutations in the BRCA1 or BRCA2 (BRCA1/2) genes are recommended to undergo a number of intensive cancer risk-reducing strategies, including prophylactic mastectomy, prophylactic oophorectomy, and screening. We estimate the impact of different risk-reducing options at various ages on life expectancy.

Methods: We apply our previously developed Monte Carlo simulation model of screening and prophylactic surgery in BRCA1/2 mutation carriers. Here, we present the mathematical formulation to compute age-specific breast cancer incidence in the absence of prophylactic oophorectomy, which is an input to the simulation model, and provide sensitivity analysis on related model parameters.

Results: The greatest gains in life expectancy result from conducting prophylactic mastectomy and prophylactic oophorectomy immediately after BRCA1/2 mutation testing; these gains vary with age at testing, from 6.8 to 10.3 years for BRCA1 and 3.4 to 4.4 years for BRCA2 mutation carriers. Life expectancy gains from delaying prophylactic surgery by 5 to 10 years range from 1 to 9.9 years for BRCA1 and 0.5 to 4.2 years for BRCA2 mutation carriers. Adding annual breast screening provides gains of 2.0 to 9.9 years for BRCA1 and 1.5 to 4.3 years for BRCA2. Results were most sensitive to variations in our assumptions about the magnitude and duration of breast cancer risk reduction due to prophylactic oophorectomy.

Conclusions: Life expectancy gains depend on the type of BRCA mutation and age at interventions. Sensitivity analysis identifies the degree of breast cancer risk reduction due to prophylactic oophorectomy as a key determinant of life expectancy gain.

Impact: Further study of the impact of prophylactic oophorectomy on breast cancer risk in BRCA1/2 mutation carriers is warranted.

Citing Articles

A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.

Leggat-Barr K, Yee D, Duralde E, Hodge C, Borges V, Baxter M Breast Cancer Res Treat. 2024; 209(1):1-14.

PMID: 39531132 PMC: 11785669. DOI: 10.1007/s10549-024-07522-4.

A simple framework to identify optimal cost-effective risk thresholds for a single screen: Comparison to Decision Curve Analysis.

Katki H, Bebu I J R Stat Soc Ser A Stat Soc. 2022; 184(3):887-903.

PMID: 35702631 PMC: 9190212. DOI: 10.1111/rssa.12680.

Targeted BRCA1/2 population screening among Ashkenazi Jewish individuals using a web-enabled medical model: An observational cohort study.

Morgan K, Hamilton J, Symecko H, Kamara D, Jenkins C, Lester J Genet Med. 2021; 24(3):564-575.

PMID: 34906490 PMC: 9306016. DOI: 10.1016/j.gim.2021.10.016.

Making Sense of a Health Threat: Illness Representations, Coping, and Psychological Distress among Mutation Carriers.

Brand H, Speiser D, Besch L, Roseman J, Kendel F Genes (Basel). 2021; 12(5).

PMID: 34069035 PMC: 8156260. DOI: 10.3390/genes12050741.

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers.

Heemskerk-Gerritsen B, Jager A, Koppert L, Obdeijn A, Collee M, Meijers-Heijboer H Breast Cancer Res Treat. 2019; 177(3):723-733.

PMID: 31302855 PMC: 6745043. DOI: 10.1007/s10549-019-05345-2.

References

Grann V, Patel P, Jacobson J, Warner E, Heitjan D, Ashby-Thompson M . Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Res Treat. 2010; 125(3):837-47. PMC: 3615889. DOI: 10.1007/s10549-010-1043-4. View

Kurian A, Sigal B, Plevritis S . Survival analysis of cancer risk reduction strategies for BRCA1/2 mutation carriers. J Clin Oncol. 2009; 28(2):222-31. PMC: 2815712. DOI: 10.1200/JCO.2009.22.7991. View

Plevritis S, Kurian A, Sigal B, Daniel B, Ikeda D, Stockdale F . Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging. JAMA. 2006; 295(20):2374-84. DOI: 10.1001/jama.295.20.2374. View

Kurian A, Munoz D, Rust P, Schackmann E, Smith M, Clarke L . Online tool to guide decisions for BRCA1/2 mutation carriers. J Clin Oncol. 2012; 30(5):497-506. PMC: 3295552. DOI: 10.1200/JCO.2011.38.6060. View

Grann V, Panageas K, Whang W, Antman K, Neugut A . Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1-positive or BRCA2-positive patients. J Clin Oncol. 1998; 16(3):979-85. DOI: 10.1200/JCO.1998.16.3.979. View

Tengs T, Winer E, Paddock S, Berry D . Testing for the BRCA1 and BRCA2 breast-ovarian cancer susceptibility genes: a decision analysis. Med Decis Making. 1999; 18(4):365-75. DOI: 10.1177/0272989X9801800402. View

Plevritis S, Sigal B, Salzman P, Rosenberg J, Glynn P . A stochastic simulation model of U.S. breast cancer mortality trends from 1975 to 2000. J Natl Cancer Inst Monogr. 2006; (36):86-95. DOI: 10.1093/jncimonographs/lgj012. View

Rebbeck T, Friebel T, Lynch H, Neuhausen S, van t Veer L, Garber J . Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004; 22(6):1055-62. DOI: 10.1200/JCO.2004.04.188. View

Leach M, Boggis C, Dixon A, Easton D, Eeles R, Evans D . Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study (MARIBS). Lancet. 2005; 365(9473):1769-78. DOI: 10.1016/S0140-6736(05)66481-1. View

10.

Evans D, Young K, Bulman M, Shenton A, Wallace A, Lalloo F . Probability of BRCA1/2 mutation varies with ovarian histology: results from screening 442 ovarian cancer families. Clin Genet. 2008; 73(4):338-45. DOI: 10.1111/j.1399-0004.2008.00974.x. View

11.

Finch A, Beiner M, Lubinski J, Lynch H, Moller P, Rosen B . Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006; 296(2):185-92. DOI: 10.1001/jama.296.2.185. View

12.

Lakhani S, Manek S, Penault-Llorca F, Flanagan A, Arnout L, Merrett S . Pathology of ovarian cancers in BRCA1 and BRCA2 carriers. Clin Cancer Res. 2004; 10(7):2473-81. DOI: 10.1158/1078-0432.ccr-1029-3. View

13.

Rebbeck T, Lynch H, Neuhausen S, Narod S, Veer L, Garber J . Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002; 346(21):1616-22. DOI: 10.1056/NEJMoa012158. View

14.

Anderson K, Jacobson J, Heitjan D, Graff Zivin J, Hershman D, Neugut A . Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation. Ann Intern Med. 2006; 144(6):397-406. DOI: 10.7326/0003-4819-144-6-200603210-00006. View

15.

Chen S, Parmigiani G . Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007; 25(11):1329-33. PMC: 2267287. DOI: 10.1200/JCO.2006.09.1066. View

16.

Schrag D, Kuntz K, Garber J, Weeks J . Decision analysis--effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med. 1997; 336(20):1465-71. DOI: 10.1056/NEJM199705153362022. View

17.

Plevritis S, Salzman P, Sigal B, Glynn P . A natural history model of stage progression applied to breast cancer. Stat Med. 2006; 26(3):581-95. DOI: 10.1002/sim.2550. View

18.

Parker W, Broder M, Liu Z, Shoupe D, Farquhar C, Berek J . Ovarian conservation at the time of hysterectomy for benign disease. Obstet Gynecol. 2005; 106(2):219-26. DOI: 10.1097/01.AOG.0000167394.38215.56. View

19.

Kriege M, Brekelmans C, Boetes C, Besnard P, Zonderland H, Obdeijn I . Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med. 2004; 351(5):427-37. DOI: 10.1056/NEJMoa031759. View

20.

Kuhl C, Schrading S, Leutner C, Morakkabati-Spitz N, Wardelmann E, Fimmers R . Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. J Clin Oncol. 2005; 23(33):8469-76. DOI: 10.1200/JCO.2004.00.4960. View